• Dr. Byrne is an accomplished and creative scientist performing research at the international level both in the academia and in industry. He has more than 25 years of industry and academic research experience involving development of new technologies in gene regulation, drug development, immunology, and critical advances in the xenotransplantation field. He pioneered the development of binary gene regulation methods for controlling gene expression in transgenic animals using the Herpes simplex virus VP16 transactivator. This work culminated in an early transgenic mouse patent (Patent #5,221,778) and later development of tetracycline repressor based gene regulation (Patent # 5,917,122). Binary gene regulation is now commonly used in transgenic research.

    As Director of Research and Development at Nextran, Inc., a subsidiary of Baxter International, the team he managed was responsible for developing Gal-specific drugs to modulate the anti-Gal antibody response in nonhuman primates and for developing genetically modified pigs with a targeted mutation in the -galactosyl transferase gene thereby creating a strain of pigs deficient in production of the major xenogeneic antigen. He had broad responsibility for molecular analysis of transgenic pigs and immunological analysis of pig-to-primate cardiac xenotransplantation. Dr. Byrne created a variety of transgenic pigs for xenotransplantation and produced the first transgenic pig line approved for use in an FDA approved clinical trial.

    At Mayo Clinic, he continued his research in xenotransplantation and led the field in using proteomic and genetic screening to define new non-Gal pig antigens that contribute to xenograft rejection. This led to the seminal identification of the SDa blood group as a significant xenogeneic glycan in pig tissue. He was the first in the field to apply modern genome wide scanning methods to the analysis of xenograft rejection.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 A Durable Porcine Pericardial Surgical Bioprosthetic Heart Valve: a Proof of ConceptJournal of Cardiovascular Translational Research.  12:331-337. 2019
    2018 B4GALNT2 and xenotransplantation: A newly appreciated xenogeneic antigenXenotransplantation.  25. 2018
    2018 PERVading strategies and infectious risk for clinical xenotransplantationXenotransplantation.  25. 2018
    2018 Does human leukocyte antigens sensitization matter for xenotransplantation?Xenotransplantation.  25. 2018
    2018 Prosthesis type for aortic-and mitral-valve replacementNew England Journal of Medicine.  378:776-777. 2018
    2017 Porcine to Human Heart Transplantation: Is Clinical Application Now Appropriate?Journal of Immunology Research.  2017. 2017
    2016 Physical equivalency of wild type and galactose α 1,3 galactose free porcine pericardium; a new source material for bioprosthetic heart valvesOperative Techniques in Orthopaedics.  41:204-209. 2016
    2015 A pig-to-mouse coronary artery transplantation model for investigating the pathogenicity of anti-pig antibodyXenotransplantation.  22:458-467. 2015
    2015 Current status of pig heart xenotransplantationInternational Journal of Surgery.  23:234-239. 2015
    2015 Recent investigations into pig antigen and anti-pig antibody expressionInternational Journal of Surgery.  23:223-228. 2015
    2014 Cloning and expression of porcine β1,4 N-acetylgalactosaminyl transferase encoding a new xenoreactive antigenXenotransplantation.  21:543-554. 2014
    2014 Development of a consensus protocol to quantify primate anti-non-Gal xenoreactive antibodies using pig aortic endothelial cellsXenotransplantation.  21:555-566. 2014
    2014 First quantification of alpha-Gal epitope in current glutaraldehyde-fixed heart valve bioprosthesis (by Naso et al.)Xenotransplantation.  21:11-12. 2014
    2013 Histopathologic insights into the mechanism of anti-non-Gal antibody-mediated pig cardiac xenograft rejectionXenotransplantation.  20:292-307. 2013
    2013 Gal-knockout bioprostheses exhibit less immune stimulation compared to standard biological heart valves.Journal of Heart Valve Disease.  22:383-390. 2013
    2012 Human CD55 expression blocks hyperacute rejection and restricts complement activation in gal knockout cardiac xenograftsTransplantation.  93:686-692. 2012
    2012 Cardiac xenotransplantation: Progress and challengesInternational Journal of Clinical and Laboratory Research.  17:148-154. 2012
    2011 Reply to the EditorJournal of Thoracic and Cardiovascular Surgery.  142:239. 2011
    2011 Comparison of gal and non-gal-mediated cardiac xenograft rejectionTransplantation.  91:968-975. 2011
    2011 Identification of new carbohydrate and membrane protein antigens in cardiac XenotransplantationTransplantation.  91:287-292. 2011
    2011 Cardiac xenotransplantation technology provides materials for improved bioprosthetic heart valvesJournal of Thoracic and Cardiovascular Surgery.  141:269-275. 2011
    2011 Changes in cardiac gene expression after pig-to-primate orthotopic xenotransplantationXenotransplantation.  18:14-27. 2011
    2011 Coagulopathy in α-galactosyl transferase knockout pulmonary xenotransplantsXenotransplantation.  18:6-13. 2011
    2010 Prolonged Cardiac Allograft Survival Using Iodine 131 After Human Sodium Iodide Symporter Gene Transfer in A Rat ModelTransplantation Proceedings.  42:1888-1894. 2010
    2010 Rat model in the study of the role of α-gal in heart valve bioprostheses calcificationThe Journal of heart transplantation.  29:912-913. 2010
    2010 Gal knockout pig pericardium: New source of material for heart valve bioprosthesesThe Journal of heart transplantation.  29:538-543. 2010
    2008 Proteomic identification of non-Gal antibody targets after pig-to-primate cardiac xenotransplantationXenotransplantation.  15:268-276. 2008
    2008 Efficient and Durable Gene Transfer to Transplanted Heart Using Adeno-associated Virus 9 VectorThe Journal of heart transplantation.  27:554-560. 2008
    2008 Expression of complement regulatory proteins in accommodated xenografts induced by anti-α-Gal IgG1 in a rat-to-mouse modelAmerican Journal of Biochemistry and Biotechnology.  8:32-40. 2008
    2008 Non-invasive radioiodine imaging for accurate quantitation of NIS reporter gene expression in transplanted heartsEuropean Journal of Cardio-Thoracic Surgery.  33:32-39. 2008
    2007 The Utility of Right Ventricular Endomyocardial Biopsy for the Diagnosis of Xenograft Rejection After CD46 Pig-to-Baboon Cardiac TransplantationThe Journal of heart transplantation.  26:1025-1032. 2007
    2006 Increased immunosuppression, not anticoagulation, extends cardiac xenograft survivalTransplantation.  82:1787-1791. 2006
    2006 T-cell responses during pig-to-primate xenotransplantationXenotransplantation.  13:31-40. 2006
    2005 Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft functionAmerican Journal of Biochemistry and Biotechnology.  5:1011-1020. 2005
    2005 Prevention, detection, and management of early bacterial and fungal infections in a preclinical cardiac xenotransplantation model that achieves prolonged survivalXenotransplantation.  12:127-133. 2005
    2005 Cardiac xenotransplantation: Recent preclinical progress with 3-month median survivalJournal of Thoracic and Cardiovascular Surgery.  130:844.e1-844.e9. 2005
    2004 Cardiac xenotransplantation: Progress toward the clinicTransplantation.  78:1569-1575. 2004
    2004 Effective antiplatelet therapy does not prolong transgenic pig to baboon cardiac xenograft survivalXenotransplantation.  11:436-443. 2004
    2004 Cutting edge: NK cells mediate IgG1-dependent hyperacute rejection of xenograftsJournal of Immunology.  172:7235-7238. 2004
    2003 Serologic analysis of anti-porcine endogenous retroviruses immune responses in humans after ex vivo transgenic pig liver perfusionKZfSS Kölner Zeitschrift für Soziologie und Sozialpsychologie.  49:407-416. 2003
    2003 Pig cells that lack the gene for α1-3 galactosyltransferase express low levels of the gal antigenTransplantation.  75:430-436. 2003
    2003 The in vitro and in vivo effects of anti-galactose antibodies on endothelial cell activation and xenograft rejectionJournal of Immunology.  170:1531-1539. 2003
    2003 Skin graft survival in genetically identical cloned pigsClinical Diabetes.  5:117-121. 2003
    2002 Analysis of the control of the anti-gal immune response in a non-human primate by galactose α1-3 galactose trisaccharide-polyethylene glycol conjugateTransplantation.  73:1780-1787. 2002
    2002 Evaluation of different α-galactosyl glycoconjugates for use in xenotransplantationTurkish Journal of Medical Sciences.  13:571-581. 2002
    2002 Development and characterization of anti-Gal B cell receptor transgenic Gal-/-miceTransplantation.  73:1549-1557. 2002
    2002 CTLA-4lg in combination with anti-CD40L prolongs xenograft survival and inhibits anti-Gal Ab production in GT-Ko miceAmerican Journal of Biochemistry and Biotechnology.  2:41-47. 2002
    2001 The structure of anti-Gal immunoglobulin genes in naïve and stimulated Gal knockout miceTransplantation.  72:1817-1825. 2001
    2001 Tetracycline-inducible systems for DrosophilaProceedings of the National Academy of Sciences.  98:10775-10780. 2001
    2001 The effect of anti-αGal antibody removal with immunoabsorption and splenectomy on CD46 transgenic kidney xenograft survivalTransplantation Proceedings.  33:721-722. 2001
    2000 The role of anti-Galα1-3Gal antibodies in acute vascular rejection and accommodation of xenograftsTransplantation.  70:1667-1674. 2000
    2000 Non-depleting anti-CD4, but not anti-CD8, antibody induces long-term survival of xenogeneic and allogeneic hearts in α1,3-galactosyltransferase knockout (GT-Ko) miceXenotransplantation.  7:275-283. 2000
    2000 Anti-galactose-α(1,3) galactose antibody production in α1,3-galactosyltransferase gene knockout mice after xeno and allo transplantationTransplant Immunology.  8:129-137. 2000
    2000 The role of antibodies in dysfunction of pig-to-baboon pulmonary transplantsJournal of Thoracic and Cardiovascular Surgery.  120:29-38. 2000
    1999 Human complement regulatory proteins protect swine lungs from xenogeneic injurySchizophrenia Bulletin.  67:769-775. 1999
    1998 Complement-mediated pulmonary xenograft injury: Studies in swine-to- primate orthotopic single lung transplant modelsTransplantation.  65:1084-1093. 1998
    1998 The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplantsJournal of Clinical Investigation.  101:1745-1756. 1998
    1998 Glycosyl phosphatidylinositol anchorNephron.  6:148-151. 1998
    1997 Humoral responses to pig-to-baboon cardiac transplantation: Implications for the pathogenesis and treatment of acute vascular rejection and for accommodationHuman Immunology.  58:91-105. 1997
    1997 Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damageTransplantation.  63:149-155. 1997
    1997 Swine lungs expressing human complement-regulatory proteins are protected against acute pulmonary dysfunction in a human plasma perfusion modelJournal of Thoracic and Cardiovascular Surgery.  113:390-398. 1997
    1996 Development and analysis of transgenic pigs expressing the human complement regulatory proteins CD59 and DAFTransplantation Proceedings.  28:759. 1996
    1996 Spatial and temporal regulation of a lacZ reporter transgene in a binary transgenic mouse systemTransgenic Research.  5:37-48. 1996
    1995 Protection of xenogeneic cardiac endothelium from human complement by expression of cd59 or daf in transgenic miceTransplantation.  60:1149-1156. 1995
    1995 Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusionTransplantation.  59:1177-1182. 1995
    1995 In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endotheliumScience.  269:89-92. 1995
    1994 Demonstration of intermembrane transfer of CD59 during coculture of human erythrocytes with porcine and bovine aortic endothelial cellsTransplantation Proceedings.  26:1240. 1994
    1994 Erythroid-specific expression of human CD59 and transfer to vascular endothelial cellsTransplantation Proceedings.  26:1241. 1994
    1994 Expression of complement regulatory factors using heterologous promoters in transgenic miceTransplantation Proceedings.  26:1242. 1994
    1991 Analysis of regulatory genes using the transgenic mouse system.Nurse Practitioner Alliance of Alabama Newsletter.  16:135-152. 1991
    1989 Multiplex gene regulation: A two-tiered approach to transgene regulation in transgenic miceProceedings of the National Academy of Sciences.  86:5473-5477. 1989
    1988 Spatial patterns in the fruiting bodies of the cellular slime mold Polysphondylium pallidumInvestigational New Drugs.  38:73-81. 1988
    1987 Branching in Polysphondylium whorls: Two-dimensional patterning in a three-dimensional systemAging Today.  119:302-304. 1987
    1987 Genesis of a spatial pattern in the cellular slime mold Polysphondylium pallidumProceedings of the National Academy of Sciences.  84:4140-4144. 1987
    1986 Spatial patterning in Polysphondylium: Monoclonal antibodies specific for whorl prepatternsAging Today.  117:442-455. 1986
    1982 Pattern Formation and Tip Inhibition in the Cellular Slime Mold Polysphondylium pallidumInvestigational New Drugs.  23:103-108. 1982

    Research Overview

  • His current research interests at UCL centre on translational research leveraging the expertise and resources developed for xenotransplantation to advance development of new platforms for improved bioprosthetic devices for treating cardiovascular disease.
  • Education And Training

  • Doctor of Science in Biology / Biological Sciences, Princeton University 1986
  • Bachelor of Arts in Biology, University of Delaware 1980
  • Full Name

  • Guerard Byrne